AMYLOIDOSIS
Clinical trials for AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New chemo formula aims for fewer side effects in cancer treatment
Disease control OngoingThis study is testing a new, more stable version of a standard chemotherapy drug called melphalan. It is for adults with multiple myeloma or AL amyloidosis who are getting a stem cell transplant. The goal is to see if this new formulation can be dosed more precisely and cause few…
Matched conditions: AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
One-Shot gene therapy aims to halt rare, devastating nerve disease
Disease control OngoingThis Phase 3 trial is testing whether a single dose of an experimental gene therapy called NTLA-2001 can safely slow or stop the progression of hereditary amyloidosis with polyneuropathy (ATTRv-PN), a rare genetic disease that damages nerves. About 50 participants worldwide will …
Matched conditions: AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo tested for rare, Heart-Damaging protein disease
Disease control OngoingThis study is testing a treatment called D-VCd (daratumumab plus other drugs) for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up and damage organs, especially the heart. The main goals are to check the treatment's safety for the heart …
Matched conditions: AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC